Pellizzari Christine A

SEC source: 0001437749-26-025671 · rdgdoc.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,076

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001437749-26-018550 · rdgdoc.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,142

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001127430-26-000002 · form4-01282026_040103.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,230

Underlying: Common Stock · 1,230 shares

Expires 2036-01-26

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) January 27, 2027, or (ii) the day of the Issuer's 2026 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001437749-26-000608 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 4,827

Underlying: Common Stock · 4,827 shares

Expires 2036-01-02

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of the grant

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-25-025100 · rdgdoc.xml · derivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 250

Underlying: Common Stock · 250 shares

Expires 2035-08-04

F2 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F3 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-25-025100 · rdgdoc.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 2,248

F1 · shares: Stock granted in lieu of cash for portion of board fees

SEC source: 0001437749-25-008259 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 3,750

Underlying: Common Stock · 3,750 shares

Expires 2035-03-14

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-24-028883 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 23,630

Underlying: Common Stock · 4,964 shares

Expires 2034-09-06

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F3 · shares: Option granted in lieu of cash for portion of board fees.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001415889-24-017012 · form4-06142024_060608.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 16,000

Underlying: Common Stock · 16,000 shares

Expires 2034-06-12

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 13, 2025, or (ii) the day of the Issuer's 2025 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001437749-24-020257 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 18,666

Underlying: Common Stock · 4,500 shares

Expires 2034-06-12

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001437749-24-008337 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 14,166

Underlying: Common Stock · 4,500 shares

Expires 2034-03-15

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/2 on the date of grant; 1/4 on the one year anniversary of the date of grant; and 1/4 on the second year anniversary of the date of grant.

SEC source: 0001819113-24-000020 · wk-form4_1710252461.xml · derivative · entry 4

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 428 shares

Expires not disclosed

F5 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time.

F5 · price: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time.

F5 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time.

F5 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, all "Earn-Out Rights" (that is, all rights to receive Issuer Common Stock that were reserved for issuance as "Earn-Out Shares" pursuant to, and under the circumstances set forth in, Section 2.8 of the Agreement and Plan of Merger dated as of May 6, 2021 by and among the Issuer, LifeSci Acquisition II Corp. and LifeSci Acquisition II Merger Sub, Inc.) that were outstanding immediately prior to the Effective Time automatically were cancelled and ceased to exist at the Effective Time.

SEC source: 0001819113-24-000020 · wk-form4_1710252461.xml · derivative · entry 3

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 37,222 shares

Expires not disclosed

F3 · derivative.exercise_price: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

F4 · derivative.exercise_price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

F3 · price: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

F3 · derivative.exercise_date: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

F4 · derivative.exercise_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

F3 · derivative.expiration_date: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

F4 · derivative.expiration_date: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

SEC source: 0001819113-24-000020 · wk-form4_1710252461.xml · nonDerivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F3 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person. Each RSU represented a contingent right to receive one share of Issuer Common Stock upon vesting of the RSU.

F4 · price: Pursuant to the Merger Agreement, at the Effective Time, each RSU that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Issuer Common Stock subject to such RSU.

SEC source: 0001819113-24-000020 · wk-form4_1710252461.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

F1 · shares: Includes 125 shares acquired under the issuer's Employee Stock Purchase Plan and includes 78 shares that were inadvertently omitted from holdings on the Reporting Person's prior Form 4.

F2 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer ("Issuer Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"). After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer.

SEC source: 0001819113-23-000067 · wk-form4_1692130786.xml · derivative · entry 3

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 711,097

Underlying: Common Stock · 355,549 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Science 37 Holdings, Inc.'s common stock.

F4 · derivative.exercise_date: On August 12, 2022, Ms. Pellizzari received restricted stock units representing 1,066,646 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

F4 · derivative.expiration_date: On August 12, 2022, Ms. Pellizzari received restricted stock units representing 1,066,646 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

SEC source: 0001819113-23-000067 · wk-form4_1692130786.xml · nonDerivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 989,857

F2 · shares: Disposition of common stock resulting from the withholding of securities for the payment of tax liability relating to the vesting of the restricted stock units granted to Ms. Pellizzari on August 12, 2022.

SEC source: 0001819113-23-000067 · wk-form4_1692130786.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 1,076,434

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquisition of common stock resulting from vesting of the restricted stock units granted to Ms. Pellizzari on August 12, 2022.

SEC source: 0001209191-23-038443 · doc4.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 8,200

Underlying: Common Stock · 8,200 shares

Expires 2033-06-14

F1 · derivative.exercise_date: The shares underlying the option will vest in full on the earlier of (i) June 15, 2024, or (ii) the day of the Issuer's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

SEC source: 0001819113-23-000054 · wf-form4_168478913242280.xml · derivative · entry 3

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 33,333

Underlying: Common Stock · 16,667 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Science 37 Holdings, Inc.'s common stock.

F4 · derivative.exercise_date: On May 20, 2022, Ms. Pellizzari received restricted stock units representing 50,000 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

F4 · derivative.expiration_date: On May 20, 2022, Ms. Pellizzari received restricted stock units representing 50,000 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

SEC source: 0001819113-23-000054 · wf-form4_168478913242280.xml · nonDerivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 720,885

F2 · shares: Disposition of common stock resulting from the withholding of securities for the payment of tax liability relating to the vesting of one-third of the restricted stock units granted to Ms. Pellizzari on May 20, 2022.

SEC source: 0001819113-23-000054 · wf-form4_168478913242280.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 726,499

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · shares: Acquisition of common stock resulting from vesting of the restricted stock units granted to Ms. Pellizzari on May 20, 2022.

SEC source: 0001819113-23-000033 · wf-form4_168305881849181.xml · derivative · entry 4

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 247,000 shares

Expires 2031-10-07

F3 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 247,000 shares of common stock of the issuer and in exchange issued to the reporting person 98,800 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F3 · derivative.exercise_date: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 247,000 shares of common stock of the issuer and in exchange issued to the reporting person 98,800 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

SEC source: 0001819113-23-000033 · wf-form4_168305881849181.xml · derivative · entry 3

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 238,095 shares

Expires 2032-01-07

F2 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 238,095 shares of common stock of the issuer and in exchange issued to the reporting person 95,237 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F2 · derivative.exercise_date: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 238,095 shares of common stock of the issuer and in exchange issued to the reporting person 95,237 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

SEC source: 0001819113-23-000033 · wf-form4_168305881849181.xml · derivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 1,270,739 shares

Expires 2031-07-20

F6 · shares: The total amount has been adjusted to add 29 derivative securities that were not previously included due to a rounding error.

F1 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 1,270,739 shares of common stock of the issuer and in exchange issued to the reporting person 508,295 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F1 · derivative.exercise_date: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 1,270,739 shares of common stock of the issuer and in exchange issued to the reporting person 508,295 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

SEC source: 0001819113-23-000033 · wf-form4_168305881849181.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal and HR Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 709,832

F1 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 1,270,739 shares of common stock of the issuer and in exchange issued to the reporting person 508,295 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F2 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 238,095 shares of common stock of the issuer and in exchange issued to the reporting person 95,237 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F3 · price: On April 28, 2023, the issuer cancelled, pursuant to the issuer's option exchange program, options to purchase 247,000 shares of common stock of the issuer and in exchange issued to the reporting person 98,800 restricted stock units, each of which represents a contingent right to receive one share of the issuer's common stock.

F4 · balance_after: Includes 2,500 shares acquired under the issuer's Employee Stock Purchase Plan.

F5 · balance_after: Includes 702,332 restricted stock units, which will vest in three equal annual installments beginning on April 28, 2024, subject to continued employment.

SEC source: 0001437749-23-007408 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 9,666

Underlying: Common Stock · 2,000 shares

Expires 2033-03-17

F1 · derivative.exercise_price: Represents the closing price of Imunon, Inc. Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant.

SEC source: 0001819113-22-000105 · wf-form4_166872126315724.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,000

SEC source: 0001819113-22-000061 · wf-form4_166068084991563.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,066,646

Underlying: Common Stock · 1,066,646 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Science 37 Holdings, Inc.'s common stock.

F2 · derivative.exercise_date: On August 12, 2022, Ms. Pellizzari received restricted stock units representing 1,066,646 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

F2 · derivative.expiration_date: On August 12, 2022, Ms. Pellizzari received restricted stock units representing 1,066,646 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

SEC source: 0001179110-22-003383 · edgar.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,500

Underlying: Common Stock · 3,500 shares

Expires 2032-06-16

F1 · derivative.exercise_date: Vests over one (1) year, with one hundred per cent (100%) of the award vesting on the first anniversary of the date of grant subject to the reporting person's continuous service through the vesting date.

SEC source: 0001437749-22-015065 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 7,666

Underlying: Celsion Corporation Common Stock · 2,500 shares

Expires 2032-06-13

F1 · derivative.exercise_price: Represents the per share fair value of the Common Stock based on the closing price of a share of Celsion Corporation Common Stock on the date of the grant.

F2 · derivative.exercise_date: The Options vest as follows: 1/3 on the date of the grant, 1/3 on the one year anniversary of the date of the grant, and 1/3 on the second year anniversary of the date of the grant.

SEC source: 0001819113-22-000041 · wf-form4_165342348865482.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 50,000

Underlying: Common Stock · 50,000 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Science 37 Holdings, Inc.'s common stock.

F2 · derivative.exercise_date: On May 20, 2022, Ms. Pellizzari received restricted stock units representing 50,000 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

F2 · derivative.expiration_date: On May 20, 2022, Ms. Pellizzari received restricted stock units representing 50,000 shares subject to a three-year vesting schedule, vesting 33 1/3% on the first, second and third anniversaries of the grant date. As restricted stock units vest, the vested units are automatically converted to vested common stock on a one-for-one basis on the vesting date.

SEC source: 0001437749-22-005429 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 5,166

Underlying: Celsion Corporation Common Stock · 2,500 shares

Expires 2032-03-04

F1 · derivative.exercise_price: Represents the per share value of the Common Stock on the closing price of a share of Celsion Corporation Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/3 on the date of grant; 1/3 on the one year anniversary of the date of grant; and 1/3 on the second year anniversary of the date of grant.

SEC source: 0001104659-22-003321 · tm222701-4_4seq1.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 238,095

Underlying: Common Stock · 238,095 shares

Expires 2032-01-07

F1 · derivative.exercise_date: The Stock Option shall vest and become exercisable as to 25% of the shares of Common Stock subject thereto on January 7, 2023, and the remaining underlying shares will vest in equal monthly installments until fully vested on January 7, 2026, subject to the grantee's continued service as a Service Provider through each applicable vesting date.

SEC source: 0001104659-21-125570 · tm2129868-7_4seq1.xml · derivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 247,000

Underlying: Common Stock · 247,000 shares

Expires 2031-10-07

F3 · derivative.exercise_date: The Stock Option shall vest and become exercisable as to 25% of the shares of Common Stock subject thereto on July 8, 2022, and the remaining underlying shares will vest in equal monthly installments until fully vested on July 8, 2025, subject to the grantee's continued service as a Service Provider through each applicable vesting date.

SEC source: 0001104659-21-124838 · tm2129593d18_4.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,270,710

Underlying: Common Stock · 1,270,710 shares

Expires 2031-07-20

F1 · price: Pursuant to the business combination of LifeSci Acquisition II Corp and Science 37, Inc. ("Old Science 37"), as contemplated by that certain agreement and plan of merger, dated May 6, 2021 (the "Merger Agreement"), (a) each share of common stock of Old Science 37 outstanding immediately prior to the effective time of the business combination was converted into approximately 1.8153 shares of the Issuer's Common Stock, (b) (the "Conversion Ratio"); and (b) each outstanding stock option of Old Science 37 was converted into a corresponding option to purchase shares of the Issuer's Common Stock as adjusted for the Conversion Ratio

F2 · derivative.exercise_date: Represents an option vesting with respect to 25% of the shares subject to the option on the first anniversary of the vesting start date, July 8, 2021, and with respect to 1/48th of the shares subject to the option on each monthly anniversary of the applicable vesting start date thereafter, subject to the executive's continued service through the applicable vesting date.

SEC source: 0001104659-21-125570 · tm2129868-7_4seq1.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 8,541

Underlying: Common Stock · 8,541 shares

Expires not disclosed

F1 · derivative.exercise_price: On October 6, 2021, pursuant to the Agreement and Plan of Merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acquisition II Corp. (the "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Legacy Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Legacy Science 37 with Legacy Science 37 surviving such merger as a wholly-owned subsidiary of the Issuer, which subsequently changed its name to "Science 37 Holdings, Inc."

F2 · derivative.exercise_price: Pursuant to the terms of the Merger Agreement, former holders of Legacy Science 37 common stock and former holders of Legacy Science 37 options are entitled to receive their pro rata share of up to 12,500,000 additional shares of the Issuer's Common Stock (the "Earn-Out Shares") if, within the three-year period following the closing date of the Merger Agreement, the volume weighted average price of Issuer's Common Stock equals or exceeds certain thresholds. Of the Earn-Out Shares, forty percent will be issued if the volume weighted average price of the Common Stock equals or exceeds $15.00 per share for a period of at least 20 days out of 30 consecutive trading days, and the remaining sixty percent will be issued if the volume weighted average price of the Issuer's Common Stock equals or exceeds $20.00 per share for a period of at least 20 days out of 30 consecutive trading days. The issuance of such shares are subject to certain adjustments set forth in the Merger Agreement.

F1 · price: On October 6, 2021, pursuant to the Agreement and Plan of Merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acquisition II Corp. (the "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Legacy Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Legacy Science 37 with Legacy Science 37 surviving such merger as a wholly-owned subsidiary of the Issuer, which subsequently changed its name to "Science 37 Holdings, Inc."

F2 · price: Pursuant to the terms of the Merger Agreement, former holders of Legacy Science 37 common stock and former holders of Legacy Science 37 options are entitled to receive their pro rata share of up to 12,500,000 additional shares of the Issuer's Common Stock (the "Earn-Out Shares") if, within the three-year period following the closing date of the Merger Agreement, the volume weighted average price of Issuer's Common Stock equals or exceeds certain thresholds. Of the Earn-Out Shares, forty percent will be issued if the volume weighted average price of the Common Stock equals or exceeds $15.00 per share for a period of at least 20 days out of 30 consecutive trading days, and the remaining sixty percent will be issued if the volume weighted average price of the Issuer's Common Stock equals or exceeds $20.00 per share for a period of at least 20 days out of 30 consecutive trading days. The issuance of such shares are subject to certain adjustments set forth in the Merger Agreement.

F1 · derivative.exercise_date: On October 6, 2021, pursuant to the Agreement and Plan of Merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acquisition II Corp. (the "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Legacy Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Legacy Science 37 with Legacy Science 37 surviving such merger as a wholly-owned subsidiary of the Issuer, which subsequently changed its name to "Science 37 Holdings, Inc."

F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, former holders of Legacy Science 37 common stock and former holders of Legacy Science 37 options are entitled to receive their pro rata share of up to 12,500,000 additional shares of the Issuer's Common Stock (the "Earn-Out Shares") if, within the three-year period following the closing date of the Merger Agreement, the volume weighted average price of Issuer's Common Stock equals or exceeds certain thresholds. Of the Earn-Out Shares, forty percent will be issued if the volume weighted average price of the Common Stock equals or exceeds $15.00 per share for a period of at least 20 days out of 30 consecutive trading days, and the remaining sixty percent will be issued if the volume weighted average price of the Issuer's Common Stock equals or exceeds $20.00 per share for a period of at least 20 days out of 30 consecutive trading days. The issuance of such shares are subject to certain adjustments set forth in the Merger Agreement.

F1 · derivative.expiration_date: On October 6, 2021, pursuant to the Agreement and Plan of Merger, dated May 6, 2021 (the "Merger Agreement"), LifeSci Acquisition II Corp. (the "Issuer"), LifeSci Acquisition II Merger Sub, Inc. ("Merger Sub") and Science 37, Inc. ("Legacy Science 37") consummated a business combination (the "Business Combination"), in which Merger Sub merged with and into Legacy Science 37 with Legacy Science 37 surviving such merger as a wholly-owned subsidiary of the Issuer, which subsequently changed its name to "Science 37 Holdings, Inc."

F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, former holders of Legacy Science 37 common stock and former holders of Legacy Science 37 options are entitled to receive their pro rata share of up to 12,500,000 additional shares of the Issuer's Common Stock (the "Earn-Out Shares") if, within the three-year period following the closing date of the Merger Agreement, the volume weighted average price of Issuer's Common Stock equals or exceeds certain thresholds. Of the Earn-Out Shares, forty percent will be issued if the volume weighted average price of the Common Stock equals or exceeds $15.00 per share for a period of at least 20 days out of 30 consecutive trading days, and the remaining sixty percent will be issued if the volume weighted average price of the Issuer's Common Stock equals or exceeds $20.00 per share for a period of at least 20 days out of 30 consecutive trading days. The issuance of such shares are subject to certain adjustments set forth in the Merger Agreement.

SEC source: 0001140361-21-023538 · form4.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,635

Underlying: Common Stock · 6,635 shares

Expires 2031-06-30

F1 · price: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service.

F1 · derivative.exercise_date: One-fourth of the shares underlying this option vest on July 1, 2022, and the remaining shares vest in a series of 36 equal monthly installments thereafter, subject to the reporting person's continued service.

SEC source: 0001179110-21-008868 · edgar.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 6,635

Underlying: Common Stock · 6,635 shares

Expires 2031-06-30

F1 · derivative.exercise_date: Vests over three (3) years, with one-third (1/3) of the award vesting on the first anniversary of the grant date and the remainder of the award vesting in equal monthly installments thereafter, subject to the reporting person's continuous service through each vesting date.

SEC source: 0001437749-21-014425 · rdgdoc.xml · derivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 40,000

Underlying: Celsion Corporation Common Stock · 40,000 shares

Expires 2031-06-08

F1 · derivative.exercise_price: Represents the closing price of Celsion Corporation Common Stock on the date of grant.

F2 · derivative.exercise_date: The options vest as follows: 1/3 on January 1, 2022; 1/3 on January 1, 2023; and 1/3 on January 1, 2024.

SEC source: 0001140361-21-017895 · form4.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 149,985

F1 · shares: Shares withheld by the Company to satisfy tax withholding requirements on vesting of time-based restricted stock units.

SEC source: 0001140361-21-017450 · form4.xml · derivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 57,200

Underlying: Common Stock · 57,200 shares

Expires 2031-05-12

F3 · derivative.exercise_date: Stock options granted under the Company's 2019 Incentive Plan. The options become exercisable based on the following vesting schedule: twenty five percent (25%) vest on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vest on each sixth month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001140361-21-017450 · form4.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 152,531

F1 · shares: Represents Restricted Stock Units, each representing a contingent right to receive one share of Common Stock, granted pursuant to the Company's 2019 Incentive Plan. The Restricted Stock Units vest and become available as follows: twenty five (25%) percent on each anniversary of the date of grant through the fourth anniversary date of the grant.

F2 · price: Each Restricted Stock Unit was received as a grant on May 12, 2021, for no consideration.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · derivative · entry 6

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Common Stock · 15,150 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · nonDerivative · entry 4

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,721

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F3 · price: This is the weighted average sales price representing 15,150 shares sold at prices ranging from $44.75 to $45.44 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · nonDerivative · entry 3

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 155,871

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · derivative · entry 5

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 15,150

Underlying: Common Stock · 6,400 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · nonDerivative · entry 2

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 140,721

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

F2 · price: This is the weighted average sales price representing 6,400 shares sold at prices ranging from $43.75 to $44.15 per share. The reporting person undertakes to provide to the SEC staff, the issuer, or a security holder of the issuer the number of shares sold at each price within the price range upon request.

SEC source: 0001104659-21-019794 · tm213966-3_4seq1.xml · nonDerivative · entry 1

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,121

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.

SEC source: 0001104659-21-008179 · tm213966-2_4seq1.xml · derivative · entry 9

Pellizzari Christine A · CIK 0001127430 · Chief Legal Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 21,550

Underlying: Common Stock · 2,600 shares

Expires 2026-05-19

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F5 · derivative.exercise_date: The options became exercisable based on the following vesting schedule: twenty five percent (25%) vested on the first anniversary of the grant date and an additional twelve and one half percent (12.5%) vested on each six-month anniversary date thereafter through the fourth anniversary of the date of grant.